MACULAR DEGENERATION TREATMENT
Elizabeth Evans Opticians is proud to be introducing the first approved Light Delivery treatment – Photobiomodulation – for Dry AMD in the North of the UK.
“Having a family history of Age-related Macular Degeneration, our latest technology allowed me to detect the earliest macular change on my own retina. As an Optometrist I am only too aware of how this disease progresses. I decided to undergo this new treatment myself but had to travel to London for nine visits on non-consecutive days, a gruelling 700 mile round trip each time. So I decided to bring this technology north to be able to offer it to macular degeneration patients in the North and Scotland, within a much easier commuting distance.”
Elizabeth Evans, Optometrist.
Have you been diagnosed with early to mid-stage Dry Age-related Macular Degeneration (AMD) ?
Treatment at Elizabeth Evans opticians, is supported by;
Mr Andrew Luff
MA FRCS FRCS(Ophth) FRCOphth,
Sapphire Eye Care, London,
What is Photobiomodulation?
Photobiomodulation(PBM) is a form of light therapy showing promise in the control of dry AMD.
Improves Visual Acuity
Improves Contrast Sensitivity
Reduces Central Drusen Volume
Dry AMD has remained frustratingly resistant to treatment in spite of extensive research. Nutritional supplements have offered only marginal benefit and a trial of antibody injections has produced disappointing results.
Light therapy, primarily red and infrared, can help treat numerous conditions throughout the body. The science of PBM is developing rapidly with research showing potential short-term results in the earlier stages of dry AMD. This works best for those with drusen (yellowish blobs beneath the retina) rather than atrophy (loss of tissue).
PBM is thought to work in a number of ways:
Improving blood flow to the retina and its
Stimulating nitric oxide, a chemical important to the health of blood vessels.
Activating mitochondria, the tiny particles within cells that produce energy.
Slow the deterioration of Dry AMD
Stabilise or improve vision
Reduce the risk of progression to wet AMD
Further info on PBM for Dry AMD is available at www.lumithera.com
Ideal patients are those showing signs of early, dry AMD (the grades currently considered suitable for nutritional supplements) and a visual acuity of 6/36 or better. A treatment course consists of nine sessions over a three-week period, each of which lasts just a few minutes. Three separate colours are used with no discomfort or potential side effects for the patient. Therapy can be offered to one or both eyes, depending on clinical findings and patient preference.
Initial studies show a significant effect with a benefit maintained over six months. A second treatment at that point appears once again to deliver a positive result, but no longer-term data are, as yet, available. Further clinical trials are in progress but, given the weight of evidence and the current lack of any other effective treatment, this minimally invasive and very low-risk treatment appeals to some sufferers.
Mr Andrew Luff April 2021
First Approved Treatment for Dry Age-Related Macular Degeneration (AMD) using Photobiomodulation
Am I suitable for treatment?
Ideal patients are those showing early or intermediate dry AMD and have a visual acuity of 6/36 or better. The technique does not worsen the disease, has no side effects and is completely non-invasive.
Initial Macular Consultation
Elizabeth Evans Opticians has a special interest in Age related Macular Degeneration (AMD). We have invested in advanced technology to best examine central retinal structure, and developed tests to best assess central vision and most importantly, visual function.
This is recommended for anyone with any signs of macular changes or with a family history of AMD. Based on our findings we can monitor, at more regular intervals, advise on suitability of treatment and give appropriate advice.
Anyone wishing to undergo treatment must have this initial macula consultation to check suitability prior to the Valeda treatment. It includes a series of advanced tests of ocular structure, visual performance and visual function. These assessments will facilitate the close monitoring of your progress, and the ongoing effects and benefits of Valeda treatment over time. You must allow 2-3 hours for this consultation.
Assessment fee £295
A post-treatment assessment should be undertaken 3 months after the end of the Valeda treatment schedule. Recent research suggests that further cycles may be required to maintain the treatment benefit after an interval of six months
Monitoring fee £195
Both forms of AMD start from the same disease and result when drusen(waste products) form beneath the macula. The number and size of drusen increase leading to a progressive loss of central vision over time. As the disease progresses the drusen reduce the nutrients flowing to the retina, the retina becomes very thin and fragile new vessels grow in between the cells. These vessels can leak, hence in 10% of cases of dry AMD becomes wet AMD. This can lead to a sudden aggressive loss of vision and is treated treatment is via the injection of anti vascular endothelial growth factor (anti-VEGF) drugs. These drugs inhibit the formation of the new blood vessels in the eye.
This is the is the application of low-level light therapy to a part of the body with the aim of repairing tissues and reducing inflammation, oedema and pain. It has been used for the past 20 years for musculaskeletal pain, injury, dysfunction, wound healing, neuropathic pain, lymphedema, and oral mucositis.
It is not heat therapy but is more like photosynthesis in plants. Light, in the far red and near-infrared range, can stimulate the cells, which lead to a cascade of photochemical reactions. This low-powered light is absorbed by the cells and mitochrondrial energy is then produced activating a photochemical reaction reducing oxidative stress and leading to a cellular and indirect systemic response by tissues that have not absorbed the photons.
Hence the application of PBM in Dry AMD where mitochondrial dysfunction and oxidative stress play a key role.
Photobiomodulation(PBM) as performed with the new Vaeda, acts at the mitochondrial level by improving cellular output and reestablishing metabolic function. Modulated light offers a novel valid therapeutic approach for AMD, which may facilitate the repair of damaged tissues in the retina and promote survival and function of epithelial cells within the retinal pigmented epithelium.
The technique does not worsen the disease, has no side effects, and is completely non invasive.
A treatment course will include nine sessions over a three week period. One session can be booked for example, each Monday, Wednesday and Friday (non-consecutive days) for three consecutive weeks.
Photobiomodulation is a treatment not a cure. A recent study suggested that further treatments cycles are required after six months interval to maintain benefits.
US LIGHTSITE III Trial Data Shows Improvement in Vision in Intermediate Dry Age-Related Macular Degeneration.
Read more about this exciting news
Exciting trial data (This will open in a new tab)
For the latest research please see.
Current publications on Valeda Treatment
Details of the AVRO Electrolight
Details of the Non-invasive Treatment of Early Diabetic Macular Edema